Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2017-09-25 07:45 |
Biophytis filed IND application for approval by FDA of SARA-INT Phase 2b study …
|
English | 908.5 KB | ||
| 2017-09-20 18:00 |
Biophytis sera présent à plusieurs événements sectoriels et investisseurs dans …
|
French | 713.2 KB | ||
| 2017-09-20 18:00 |
Biophytis to participate in upcoming industry and investors conferences
|
English | 708.3 KB | ||
| 2017-09-11 07:45 |
Biophytis presents the mechanism of action of Macuneos for the treatment of AMD…
|
English | 734.3 KB | ||
| 2017-09-11 07:45 |
Biophytis présente le mécanisme d’action de Macuneos dans le traitement de la …
|
French | 749.4 KB | ||
| 2017-09-08 07:45 |
Biophytis : Sarconeos, candidat médicament au stade clinique, démontre son eff…
|
French | 760.6 KB | ||
| 2017-09-08 07:45 |
Biophytis clinical stage drug-candidate Sarconeos demonstrates efficacy in prec…
|
English | 743.6 KB | ||
| 2017-08-02 18:00 |
Biophytis annonce la nomination de Manfred Horst comme Directeur Business Devel…
|
French | 728.5 KB | ||
| 2017-08-02 18:00 |
Biophytis announces the appointment of Dr Manfred Horst as Business Development…
|
English | 716.1 KB | ||
| 2017-07-31 08:00 |
BIOPHYTIS : mise à disposition du Document de Référence 2016
|
French | 109.4 KB | ||
| 2017-07-31 08:00 |
BIOPHYTIS: 2016 Reference Document made available
|
English | 107.6 KB | ||
| 2017-07-19 17:54 |
BIOPHYTIS sélectionne Appletree CI Group pour conduire MACA-OBS, et communique…
|
French | 840.8 KB | ||
| 2017-07-19 17:54 |
BIOPHYTIS selects Appletree CI Group to conduct MACA-OBS, and releases the MACA…
|
English | 786.0 KB | ||
| 2017-07-07 18:21 |
Biophytis annonce l’émission d’une tranche d’ORNANEBSA d’un montant de 3,0 M€
|
French | 699.9 KB | ||
| 2017-07-07 18:21 |
Biophytis announces the issuance of a €3 million tranche of ORNANEBSA
|
English | 694.6 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
